Immuno-Oncology – ESMO 2018

The medonline team was present at ESMO 2018 to learn about recent developments in Oncology, and to get to know the opinion of renownend experts of the field of how they think these new data will affect the current treatment standards.

Melanoma has long been at the cutting edge of immuno-oncology research, which will likely continue. The way for future headlines is already paved.

A small study, presented at ESMO Congress 2018 suggests that the orally administered fibroblast growth factor receptor (FGFR) inhibitor rogaratinib could be beneficial for a subset of patients with head and neck cancer. Dr. Markus Jörger, Kantonsspital St. Gallen, presenting the collective outcome of two combined phase I trials.

PD DDr. Sacha Rothschild from Universitätsspital Basel, reports about highlights, but also some disappointing news from day three of ESMO Congress 2018.

In this Breakfast Brief, PD DDr. Sacha Rothschild, Universitätsspital Basel, summarizes his personal highlights of the first two days of ESMO Congress 2018.

In this Breakfast Brief, PD Dr. Richard Cathomas, Kantonsspital Graubünden, Chur, presents his Immune-Oncology highlights of the first two days of ESMO Congress 2018.

Gastrointestinal (GI) malignancies remain a central focus of research and treatment within the oncology community. Colorectal cancer remains the third most common cancer diagnosed in Europe. Experts focuse extensively on new treatments for malignancies across the GI spectrum.

In the last years there has been great progress in the treatment of advanced melanoma patients and melanoma research has continued exponentially growing.

PD Dr. Dr. med. Ahmad Jalili, Director Dermatology, Bürgenstock Medical Center, held a webinar on Immunotherapie of Melanoma.

OA Dr. Maximilian Hochmair, Otto-Wagner Hospital, Vienna, held a webinar on selected highlights of the treatment of non-small lung cancer (NSCLC) from the ESMO Congress 2017.

In the randomised, double-blind phase III trial PACIFIC, durvalumab has shown to improve PFS while upholding quality of life measures in locally advanced, unresectable NSCLC patients after concurrent chemoradiation.

New research showed that among small cell lung cancer (SCLC) patients, the efficacy of using nivolumab with or without (±) ipilimumab was enhanced among those with a high tumor mutation burden (TMB).

In the 3-year-survival analysis of the phase II study POPLAR atezolizumab demonstrated superior 2-year and 3-year overall survival (OS) benefit compared with docetaxel in patients with advanced NSCLC.

Changes in LDH above the upper limit of normal values at cycle 2 and in NLR ≥ 5 at 6 weeks predicts for disease progression at the first tumour response evaluation.